Literature DB >> 2037714

Fluoxetine-induced tricyclic toxicity: extent and duration.

J Westermeyer1.   

Abstract

Combined fluoxetine-tricyclic medication has been recommended for patients who are partial responders or nonresponders to tricyclic medication alone. Three cases were encountered in which the addition of fluoxetine to tricyclic medication resulted in toxic, potentially dangerous elevations in tricyclic blood level, amounting to approximately 100-300% increases over recent tricyclic levels. In reducing the tricyclic dosage after fluoxetine, blood level decreases were behind dosage decreases; and blood level and dosage decreases were not well correlated with each other. Symptoms associated with toxic levels are described. Due to the long half-life of fluoxetine, such increases in tricyclic medication must be anticipated well in advance of initiating treatment with these two compounds. Based on these few cases, a procedure is tentatively recommended for patients on combined fluoxetine-tricyclic regimens, until such time as a definitive regimen can be developed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037714     DOI: 10.1002/j.1552-4604.1991.tb03723.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 2.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.

Authors:  Robert Z Harris; Margaret Salfi; Ed Posvar; David Hoelscher; Desmond Padhi
Journal:  Eur J Clin Pharmacol       Date:  2006-05-08       Impact factor: 2.953

Review 4.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 5.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

6.  The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

Authors:  H K Crewe; M S Lennard; G T Tucker; F R Woods; R E Haddock
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

Review 8.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

9.  Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study.

Authors:  D Baettig; G Bondolfi; S Montaldi; M Amey; P Baumann
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.